Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long

Dyadic International, Inc. (NASDAQ:DYAI) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. With the latest financial year loss of US$7.4m and a trailing-twelve-month loss of US$7.3m, the US$39m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Dyadic International's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Consensus from 3 of the American Biotechs analysts is that Dyadic International is on the verge of breakeven. They anticipate the company to incur a final loss in 2026, before generating positive profits of US$1.1m in 2027. The company is therefore projected to breakeven just over a year from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 108% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Dyadic International's upcoming projects, but, keep in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

See our latest analysis for Dyadic International

One thing we would like to bring into light with Dyadic International is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Dyadic International, so if you are interested in understanding the company at a deeper level, take a look at Dyadic International's company page on Simply Wall St. We've also put together a list of relevant aspects you should further research:

1. Valuation: What is Dyadic International worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Dyadic International is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Dyadic International’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.